Boston Scientific is expected to report Q3 2026 revenue of $4.53 billion and adjusted EPS of $0.59, with its current stock price of $87.25 trading below the analyst consensus target of $92.40. Investors are primarily focused on the commercial trajectory of the FARAPULSE Pulsed Field Ablation (PFA) system and its impact on the Cardiovascular segment's organic growth.
The company has consistently outperformed expectations driven by strong momentum in electrophysiology and recent acquisitions like Silk Road Medical. Analysts will look for updates on the integration of Axonics and any revisions to the full-year 2026 organic revenue guidance in light of shifting procedural volumes.